Disc Medicine (IRON) AI Stock Analysis

• Market Cap: $2.05B
• Dividend Yield: N/A
• Average Volume (3M): 342.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: N/A
• EPS Growth: -22.19%
• Country: US
• Employees: 94
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -1.58
• Shares Outstanding: 34,765,580
• 10 Day Avg. Volume: 375,993
• 30 Day Avg. Volume: 342,160
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -30.90K
• Enterprise Value/Ebitda: -9.27
• 1Y Price Target: $93.86
• Price Target Upside: 54.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 43 Neutral
• Price Target: ―

Disc Medicine's stock score reflects the challenges faced by biotechnology firms in early stages, with significant cash burn and negative earnings. However, a strong cash position and low leverage provide some financial stability. Technical indicators suggest mixed signals with short-term consolidation but potential longer-term weakness. Valuation metrics indicate current unprofitability, a common trait for growth-focused biotech companies.

Positive Factors

Clinical Trial Success

Compelling efficacy in the BEACON and AURORA studies with significant protoporphyrin IX reduction and sunlight tolerance improvements indicates strong potential for bitopertin's market success.

Financial Position

The company's robust financial position, with $650M in cash, is expected to fund operations into 2028, supporting ongoing and future developmental activities.

Regulatory Approval

IRON announced positive FDA feedback from a pre-NDA meeting for bitopertin in erythropoietic protoporphyria, supporting an accelerated approval pathway.

Negative Factors

Market Competition

The development continues to reinforce the accelerated approval pathway in EPP, where bitopertin will be the first drug to pursue this regulatory path.

Regulatory Challenges

The company narrowed timing guidance for NDA submission to October 2025 and reiterated plans to leverage an accelerated approval pathway.

Disc Medicine Business Overview & Revenue Model

Company Description

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

How the Company Makes Money

Disc Medicine generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company engages in research and development activities to bring new therapies to market, which involve clinical trials and regulatory approval processes. Once a drug is approved, Disc Medicine can earn revenue through direct sales, licensing agreements, and partnerships with other pharmaceutical companies. These collaborations can include milestone payments, royalties, and co-promotion deals. Additionally, the company may receive funding from grants or investment partnerships that support its research initiatives.

Disc Medicine Financial Statement Overview

Summary

Disc Medicine's financials reflect a biotechnology company in its growth phase, focused on research and development with no current revenue streams. While the company has a solid cash position and low leverage, the ongoing losses and cash burn are significant risks. Investors should weigh the potential for future profitability against current financial challenges.

Income Statement

The company has shown consistent negative net income and lacks revenue generation, which is typical for early-stage biotechnology firms. The EBIT and EBITDA margins are negative and have worsened over time, indicating increasing operational costs without revenue offset.

Balance Sheet

The company has a strong cash position relative to its debt, reflected in a negative net debt. However, the stockholders' equity is significantly high compared to total assets, indicating a favorable equity ratio. The debt-to-equity ratio is low, showing limited leverage risk, but the company has negative earnings, impacting return on equity.

Cash Flow

The operating cash flow is negative, and the free cash flow has decreased, indicating continued cash burn. However, the company maintains a solid cash buffer from previous financing activities, which offsets immediate liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-40.00K	-156.00K	-100.00K	-300.00K	-192.00K	-322.00K
EBITDA	-133.34M	-108.27M	-91.03M	-47.39M	-30.90M	-33.69M
Net Income	-145.39M	-109.36M	-76.43M	-46.83M	-35.97M	-40.84M
Balance Sheet
Total Assets	665.06M	496.77M	368.00M	200.21M	92.41M	122.09M
Cash, Cash Equivalents and Short-Term Investments	649.97M	489.88M	360.38M	194.61M	88.04M	1.21M
Total Debt	30.92M	30.00M	2.10M	1.33M	1.65M	21.64M
Total Liabilities	50.90M	53.19M	22.88M	23.61M	156.61M	4.82M
Stockholders Equity	614.16M	443.59M	345.12M	176.60M	77.65M	-21.86M
Cash Flow
Free Cash Flow	-135.56M	-94.43M	-73.55M	-42.40M	-27.60M	-32.73M
Operating Cash Flow	-134.23M	-93.93M	-73.46M	-42.25M	-27.53M	-32.71M
Investing Cash Flow	-293.46M	-292.33M	-89.00K	-151.00K	-68.00K	-22.00K
Financing Cash Flow	274.37M	218.31M	239.38M	148.98M	89.93M	34.25M

Disc Medicine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 60.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRON, the sentiment is Positive. The current price of 60.72 is above the 20-day moving average (MA) of 59.68, above the 50-day MA of 56.05, and above the 200-day MA of 54.70, indicating a bullish trend. The MACD of 1.05 indicates Positive momentum. The RSI at 55.87 is Neutral, neither overbought nor oversold. The STOCH value of 79.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRON.

Disc Medicine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGIO	58 Neutral	$2.13B	3.32	64.05%	―	30.57%	―
IMCR	58 Neutral	$1.67B	―	-5.38%	―	26.90%	62.72%
ARQT	53 Neutral	$1.92B	―	-57.33%	―	99.50%	65.91%
Sector *	51 Neutral	$7.46B	-0.25	-46.00%	2.25%	22.77%	-2.14%
BCRX	50 Neutral	$1.77B	―	18.68%	―	45.85%	76.36%
IRON	43 Neutral	$2.05B	―	-26.36%	―	―	-22.19%
BEAM	41 Neutral	$1.78B	―	-41.94%	―	-82.90%	-155.64%

Disc Medicine Corporate Events

Disc Medicine Advances Bitopertin Trial for EPP

On January 21, 2025, Disc Medicine announced positive feedback from the FDA regarding their APOLLO post-marketing confirmatory trial for bitopertin, a treatment for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The meeting resulted in alignment on the trial design, which includes key features such as co-primary endpoints and a double-blind, placebo-controlled study. The company plans to initiate the trial by mid-2025 and anticipates submitting a New Drug Application in the second half of 2025 under the Accelerated Approval Program. This development marks a significant step forward in potentially providing a life-changing therapy for EPP patients, enhancing Disc Medicine’s position in the biopharmaceutical industry.